Skip to main content
Premium Trial:

Request an Annual Quote

Mark Stevenson, David Hoffmeister, Claude Benchimol, Richard Hughes, Graham Mullis, Robert Saltmarsh, Nicholas Venuto, David Johnston

Premium
Mark Stevenson has been promoted to the position of president and chief operating officer of Applied Biosystems and senior vice president of Applera, ABI’s parent corporation.
 
Stevenson was promoted in July to executive vice president, after serving 15 months as president of the Molecular and Cellular Biology Division. Concurrent with that promotion, ABI had split the MCB Division into two groups: MCB Systems and MCB Consumables.
 
Before taking over at the helm of the MCB division, Stevenson was president of ABI’s Applied Markets division. He has been with the firm since 1998 and has held several management positions with the company.
 
Stevenson will replace Tony White, chairman, president, and CEO of Applera, who has served as interim president of ABI since October 2006, when Cathy Burzik resigned.
 

 
Invitrogen has given company CFO David Hoffmeister a raise in base salary to $475,000, and has raised VP of R&D Claude Benchimol’s salary to $420,000, according to a filing with the US Securities and Exchange Commission. The raises will take effect at the beginning of the year, the company said.
 

 
Richard Hughes of the London-based healthcare and diagnostics company Lab21 has been bumped up to head of sales and marketing and has been elected to sit on the company’s executive management team. Hughes will report directly to company CEO Graham Mullis.
 

 
Robert Saltmarsh, VP and CFO at Nanogen, plans to retire at the end of February, the company stated in an SEC filing. Nanogen also said that Nicholas Venuto, who is currently executive director of finance, will take over Saltmarsh’s duties in both positions. Nanogen also has given Venuto a hike in base salary to $220,000 and granted him the option to buy 100,000 shares of the company’s common stock.
 

 
Gene Express has appointed David Johnston to its scientific advisory board. Johnston is VP and chief scientific officer at Esoterix Clinical Trials Services, a division of Laboratory Corporation of America. Johnston has also formerly held various R&D leadership positions at LabCorp.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.